Related references
Note: Only part of the references are listed.Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2-or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine
Nicolas Folschweiller et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors
Petra J. Woestenberg et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries
Susanne K. Kjaer et al.
CLINICAL INFECTIOUS DISEASES (2018)
Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial
Li-Min Huang et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial
Warner K. Huh et al.
LANCET (2017)
Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study
Kimberley Kavanagh et al.
LANCET INFECTIOUS DISEASES (2017)
Results on exposure during pregnancy from a pregnancy registry for AS04-HPV-16/18 vaccine
Marta Lopez-Fauqued et al.
VACCINE (2017)
Ten-year immune persistence and safety of the HPV-16/18 AS04-adjuvanted vaccine in females vaccinated at 15-55years of age
Tino F. Schwarz et al.
CANCER MEDICINE (2017)
Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study
Barbara Romanowski et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
Stillbirths: rates, risk factors, and acceleration towards 2030
Joy E. Lawn et al.
LANCET (2016)
Abortion incidence between 1990 and 2014: global, regional, and subregional levels and trends
Gilda Sedgh et al.
LANCET (2016)
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study
Cosette M. Wheeler et al.
LANCET INFECTIOUS DISEASES (2016)
Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial
Dan Apter et al.
CLINICAL AND VACCINE IMMUNOLOGY (2015)
Congenital Malformations in the Newborn Population: A Population Study and Analysis of the Effect of Sex and Prematurity
Alexander Egbe et al.
PEDIATRICS AND NEONATOLOGY (2015)
Risk of spontaneous abortion and other pregnancy outcomes in 15-25 year old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom
Laurence Baril et al.
VACCINE (2015)
Long-term Immunogenicity and Safety of the HPV-16/18 AS04-adjuvanted Vaccine in 10-to 14-year-old Girls Open 6-year Follow-up of an Initial Observer-blinded, Randomized Trial
Tino F. Schwarz et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2014)
Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme
Maria-Genalin Angelo et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2014)
Post-licensure safety surveillance for human papillomavirus-16/18AS04-adjuvanted vaccine: more than 4 years of experience
Maria-Genalin Angelo et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2014)
Efficacy of the HPV-16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial
Allan Hildesheim et al.
VACCINE (2014)
Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine Final analysis of a long-term follow-up study up to 9.4 years post-vaccination
Paulo S. Naud et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types
Anne Szarewski
EXPERT REVIEW OF VACCINES (2012)
Four-Year Follow-up of the Immunogenicity and Safety of the HPV-16/18 AS04-Adjuvanted Vaccine When Administered to Adolescent Girls Aged 10-14 Years
Tino F. Schwarz et al.
JOURNAL OF ADOLESCENT HEALTH (2012)
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Matti Lehtinen et al.
LANCET ONCOLOGY (2012)
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Cosette M. Wheeler et al.
LANCET ONCOLOGY (2012)
Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women
A. -B. Moscicki et al.
VACCINE (2012)
Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women
Tiina Petaja et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Safety and Immunogenicity of the HPV-16/18 AS04-Adjuvanted Vaccine: A Randomized, Controlled Trial in Adolescent Girls
Doris M. Rivera Medina et al.
JOURNAL OF ADOLESCENT HEALTH (2010)
Cervical Human Papillomavirus Prevalence in 5 Continents: Meta-Analysis of 1 Million Women with Normal Cytological Findings
Laia Bruni et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future
Luciano Mariani et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
Silvia de Sanjose et al.
LANCET ONCOLOGY (2010)
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years
B. Romanowski et al.
LANCET (2009)
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
J. Paovonen et al.
LANCET (2009)
Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years
Tino F. Schwarz et al.
VACCINE (2009)
Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine
Francis J. Dessy et al.
HUMAN VACCINES (2008)
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women:: an interim analysis of a phase III double-blind, randomised controlled trial
Jorma Paavonen et al.
LANCET (2007)
HPV infections in adolescents
Anna-Barbara Moscicki
DISEASE MARKERS (2007)
Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
DM Harper et al.
LANCET (2006)
A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women
DR Brown et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
High incidence of cervical human papillomavirus infection in women during their first sexual relationship
S Collins et al.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY (2002)
Ectopic pregnancy
JI Tay et al.
WESTERN JOURNAL OF MEDICINE (2000)
Share Paper
